Literature DB >> 11799185

Feasibility of generating adeno-associated virus packaging cell lines containing inducible adenovirus helper genes.

Chunping Qiao1, Juan Li, Anna Skold, Xudong Zhang, Xiao Xiao.   

Abstract

The adeno-associated virus (AAV) vector system is based on nonpathogenic and helper-virus-dependent parvoviruses. The vector system offers safe, efficient, and long-term in vivo gene transfer in numerous tissues. Clinical trials using AAV vectors have demonstrated vector safety as well as efficiency. The increasing interest in the use of AAV for clinical studies demands large quantities of vectors and hence a need for improvement in vector production. The commonly used transient-transfection method, although versatile and free of adenovirus (Ad), is not cost-effective for large-scale production. While the wild-type-Ad-dependent AAV producer cell lines seem to be cost-effective, this method faces the problem of wild-type Ad contamination. To overcome these shortcomings, we have explored the feasibility of creating inducible AAV packaging cell lines that require neither transfection nor helper virus infection. As a first step toward that goal, we have created a cell line containing highly inducible Ad E1A and E1B genes, which are essential for AAV production. Subsequently, the AAV Rep and Cap genes and an AAV vector containing a green fluorescent protein (GFP) reporter gene were stably introduced into the E1A-E1B cell line, generating inducible AAV-GFP packaging cell lines. Upon induction of E1A and E1B genes and infection with replication-defective Ad with E1A, E1B, and E3 deleted, the packaging cells yielded high-titer AAV-GFP vectors. Finally, the E2, E4, and VA genes of Ad, under the control of their endogenous promoters, were also introduced into these cells. A few producer cell lines were obtained, which could produce AAV-GFP vectors upon simple drug induction. Although future improvement is necessary to increase the stability and vector yield of the cells, our study has nonetheless demonstrated the feasibility of generating helper-virus-free inducible AAV producer cell lines.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11799185      PMCID: PMC135905          DOI: 10.1128/jvi.76.4.1904-1913.2002

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  36 in total

1.  Sustained expression of therapeutic level of factor IX in hemophilia B dogs by AAV-mediated gene therapy in liver.

Authors:  L Wang; T C Nichols; M S Read; D A Bellinger; I M Verma
Journal:  Mol Ther       Date:  2000-02       Impact factor: 11.454

2.  Adeno-associated virus vector carrying human minidystrophin genes effectively ameliorates muscular dystrophy in mdx mouse model.

Authors:  B Wang; J Li; X Xiao
Journal:  Proc Natl Acad Sci U S A       Date:  2000-12-05       Impact factor: 11.205

Review 3.  Use of adeno-associated virus as a general transduction vector for mammalian cells.

Authors:  N Muzyczka
Journal:  Curr Top Microbiol Immunol       Date:  1992       Impact factor: 4.291

Review 4.  Adeno-associated viruses: an update.

Authors:  K I Berns; R A Bohenzky
Journal:  Adv Virus Res       Date:  1987       Impact factor: 9.937

Review 5.  Technology evaluation: AAV factor IX gene therapy, Avigen Inc.

Authors:  S A Fabb; J G Dickson
Journal:  Curr Opin Mol Ther       Date:  2000-10

6.  Helper-free stocks of recombinant adeno-associated viruses: normal integration does not require viral gene expression.

Authors:  R J Samulski; L S Chang; T Shenk
Journal:  J Virol       Date:  1989-09       Impact factor: 5.103

7.  Characterization of cell lines that inducibly express the adeno-associated virus Rep proteins.

Authors:  Q Yang; F Chen; J P Trempe
Journal:  J Virol       Date:  1994-08       Impact factor: 5.103

8.  Elimination of both E1 and E2 from adenovirus vectors further improves prospects for in vivo human gene therapy.

Authors:  M I Gorziglia; M J Kadan; S Yei; J Lim; G M Lee; R Luthra; B C Trapnell
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

9.  Colocalization of adeno-associated virus Rep and capsid proteins in the nuclei of infected cells.

Authors:  L A Hunter; R J Samulski
Journal:  J Virol       Date:  1992-01       Impact factor: 5.103

10.  Cell lines for the production of recombinant adeno-associated virus.

Authors:  K R Clark; F Voulgaropoulou; D M Fraley; P R Johnson
Journal:  Hum Gene Ther       Date:  1995-10       Impact factor: 5.695

View more
  6 in total

1.  A versatile adeno-associated virus vector producer cell line method for scalable vector production of different serotypes.

Authors:  Zhenhua Yuan; Chunping Qiao; Peiqi Hu; Juan Li; Xiao Xiao
Journal:  Hum Gene Ther       Date:  2011-03-18       Impact factor: 5.695

2.  A novel gene expression control system and its use in stable, high-titer 293 cell-based adeno-associated virus packaging cell lines.

Authors:  Chunping Qiao; Bing Wang; Xiaodong Zhu; Juan Li; Xiao Xiao
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

3.  A pseudo-plaque method for infectious particle assay and clonal isolation of adeno-associated virus.

Authors:  Daniel A J Mitchell; Thomas F Lerch; Joan T Hare; Michael S Chapman
Journal:  J Virol Methods       Date:  2010-08-11       Impact factor: 2.014

4.  Systemic elimination of de novo capsid protein synthesis from replication-competent AAV contamination in the liver.

Authors:  Hui Lu; Guang Qu; Xiao Yang; Ruian Xu; Weidong Xiao
Journal:  Hum Gene Ther       Date:  2011-03-23       Impact factor: 5.695

5.  Self-attenuating adenovirus enables production of recombinant adeno-associated virus for high manufacturing yield without contamination.

Authors:  Weiheng Su; Maria I Patrício; Margaret R Duffy; Jakub M Krakowiak; Leonard W Seymour; Ryan Cawood
Journal:  Nat Commun       Date:  2022-03-07       Impact factor: 14.919

6.  A concept of eliminating nonhomologous recombination for scalable and safe AAV vector generation for human gene therapy.

Authors:  Biao Dong; Andrea R Moore; Jihong Dai; Sean Roberts; Kirk Chu; Philipp Kapranov; Bernard Moss; Weidong Xiao
Journal:  Nucleic Acids Res       Date:  2013-05-15       Impact factor: 16.971

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.